Questions | Reviews **~

ceftazidime for inhalation

is there a new formulation of ceftazidime that can be administered through inhalation?
by shiela garcia in manila, philippines, 10/19/2006

Ceftazidime vx. Maxipine

What is the difference between third class and fourth class cephalosporin?  Is one more effective?  
by Pepsi in Cleveland, ohio, 10/21/2007

maximum amount of medication administered intramuscularly

what is the maximum amount (cc's) of this drug that should be administered intramuscularly with each dose?
by Hope Brooks in USA, 08/14/2007


If i am an internist doctor in what case that i should use ceftazidime? are in only nosocomial infection only>?? or are there any another case that i should give patient ceftazidime rather than ceftriaxone.. please give me as many example that u can g...
by charly caesar in indonesia,jakarta, 03/04/2006

ceftriaxone drug injection

Hello!i would like know if ceftriaxon and ceftazidime are treating the same conditions,and if so which one is more effective?
by marcela sila in tanzania, 02/09/2014

Ceftazidime (Tazidime)
(sef- TAY-zih-deem)
Pregnancy Category: B Ceptaz Fortaz Tazicef Tazidime (Rx)

Classification: Cephalosporin, third-generation

See Also: See also Anti-Infectives and Cephalosporins .

Action/Kinetics: Only for IM or IV use. t 1/2: 114-120 min. From 80% to 90% is excreted unchanged in the urine.

Uses: (1) Lower respiratory tract infections (including pneumonia) due to Pseudomonas aeruginosa and other Pseudomonas species, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella species, Enterobacter species, Proteus mirabilis, Escerichia coli, Serratia species, Citrobacter species, Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible strains). (2) Skin and skin structure infections due to P. aeruginosa, Klebsiella species, E. coli, Proteus species (including P. mirabilis and indole-positive Proteus), Enterobacter species, Serratia species, S. aureus (methicillin-susceptible strains), S. pyogenes (group A -hemolytic streptococci). (3) UTIs, both complicated and uncomplicated, due to P. aeruginosa, Enterobacter species, Proteus species (including P. mirabilis and indole-positive Proteus), Klebsiella species, and E. coli. Bacterial septicemia due to P. aeruginosa, Klebsiella species, H. influenzae, E. coli, Serratia species, S. pneumoniae, S. aureus (methicillin-susceptible strains). (4) Bone and joint infections due to P. aeruginosa, Klebsiella species, Enterobacter species, S. aureus (methicillin-susceptible strains). (5) GYN infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract, due to E. coli. (6) Intra-abdominal infections, including peritonitis, due to E. coli, Klebsiella species, S. aureus (methicillin-susceptible strains); polymicrobial infections due to aerobic and anaeraobic organisms and Bacteroides species (many strains of B. fragilis are resistant). (7) CNS infections, including meningitis, due to H. influenzae and Neisseria meningitidis (limited effect against P. aeruginosa and S. pneumoniae). Note: May be used with aminoglycosides, vancomycin, and clindamycin in severe and life-threatening infections and in the immunocompromised client.

Special Concerns: A sodium carbonate formulation should be used if the drug is indicated for children less than 12 years of age. Possible resistance when used to treat Pseudomonas aeruginosa infections.

How Supplied: Injection: 1 g, 2 g; Powder for injection: 500 mg, 1 g, 2 g, 6 g, 10 g

?IM, IV Usual infections.
Adults,IM, IV: 1 g q 8-12 hr.
UTIs, uncomplicated.
Adults, IM, IV: 0.25 g q 12 hr.
UTIs, complicated.
Adults, IM, IV: 0.5 g q 8-12 hr.
Uncomplicated pneumonia, mild skin and skin structure infections.
Adults, IM, IV: 0.5-1 g q 8 hr.
Bone and joint infections.
Adults, IV: 2 g q 12 hr.
Serious gynecologic or intra-abdominal infections, meningitis, severe or life-threatening infections (especially in immunocompromised clients).
Adults, IV: 2 g q 8 hr.
Pseudomonal lung infections in cystic fibrosis clients with normal renal function.
IV: 30-50 mg/kg q 8 hr, not to exceed 6 g/day.
Use in neonates, infants, and children.
Neonates, 0-4 weeks, IV: 30 mg/kg q 12 hr, not to exceed the adult dose. Infants and children, 1 month-12 years, IV: 30-50 mg/kg q 8 hr not to exceed 6 g/day.

Ceftazidime Ratings

Overall Rating:



(based on 2 reviews)



Ease of Use:


Overall Satisfaction:




Sure is quiet in here. You can write the first review of Ceftazidime.